[Effects of chemo-immunotherapy of malignant ovarian tumors. Collaborated study with affiliated hospitals].
D000032:Abortion, Therapeutic; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000628:therapy*; D000236:Adenoma / Q000188:drug therapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010052:Ovariectomy; D010440:Peptichemio / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy*; D011379:Prognosis
D010844:Picibanil; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio